Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Press Release
February 26, 2018

Strides Shasun to launch Ranitidine OTC Tablets
First product approval from 50:50 JV with Vivimed Labs
Product strengthens Strides Ranitidine franchise for the US markets

Bangalore, February 26, 2018 Strides Shasun Limited today announced that it will launch Ranitidine Tablets USP, 150 mg (OTC) in the US markets. Strides is already a key player in the US Ranitidine Rx market with 32% market share through its approval for Ranitidine Tablets USP, 150 mg and 300 mg. The new launch will further strengthen company’s Ranitidine franchise. According to IRI data, the US OTC market for Ranitidine Tablets, which is the generic form of the popular brand Zantac, is approximately USD 200 Million.

This is the first product approval from company’s 50:50 JV with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV’s Oral dosage facility in Chennai. Strides will have exclusive marketing rights for the product in the US. The product will be launched immediately.

The company has 82 cumulative ANDA filings with USFDA (including it’s JV with Vivimed) of which 50 ANDAs have been approved as of date and 32 are pending approval.

About Ranitidine Tablets
Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.
About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company’s website at www.stridesarco.com

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shashank Sinha, Managing Director</td>
<td>Fortuna PR</td>
</tr>
<tr>
<td>+91 80 6784 0335</td>
<td>K Srinivas Reddy: +91 90005 27213</td>
</tr>
<tr>
<td>Investors:</td>
<td><a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></td>
</tr>
<tr>
<td>Kannan. N: +91 98450 54745</td>
<td>K Priya: +91 95354 25418</td>
</tr>
<tr>
<td>Vikesh Kumar: +91 80 6784 0827</td>
<td><a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></td>
</tr>
<tr>
<td>Sandeep Baid : +91 80 6784 0791</td>
<td></td>
</tr>
</tbody>
</table>

Strides Shasun Limited
CIN : L24230MH1990PLC057062
Email: investors@stridesshasun.com